TR201902314T4 - Azol benzen türevi ve bunun kristali. - Google Patents

Azol benzen türevi ve bunun kristali. Download PDF

Info

Publication number
TR201902314T4
TR201902314T4 TR2019/02314T TR201902314T TR201902314T4 TR 201902314 T4 TR201902314 T4 TR 201902314T4 TR 2019/02314 T TR2019/02314 T TR 2019/02314T TR 201902314 T TR201902314 T TR 201902314T TR 201902314 T4 TR201902314 T4 TR 201902314T4
Authority
TR
Turkey
Prior art keywords
crystal
benzene derivative
azole benzene
azole
hyperuricemia
Prior art date
Application number
TR2019/02314T
Other languages
English (en)
Inventor
Kawana Asahi
Nozato Hisae
Kanazawa Chikashi
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of TR201902314T4 publication Critical patent/TR201902314T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Şunlar sağlanır: Gut, hiperürisemi ve benzeri için bir terapötik ajan ve bir profilaktik ajan olarak kullanışlı olan 4-metil-2-[4-(2-metilpropoksi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-1,3-tiyazol-5-karboksilik asit, bunun bir sodyum tuzu ve bunların kristalleri.
TR2019/02314T 2014-07-30 2015-07-29 Azol benzen türevi ve bunun kristali. TR201902314T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014155032 2014-07-30
JP2014155030 2014-07-30

Publications (1)

Publication Number Publication Date
TR201902314T4 true TR201902314T4 (tr) 2019-03-21

Family

ID=55217605

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02314T TR201902314T4 (tr) 2014-07-30 2015-07-29 Azol benzen türevi ve bunun kristali.

Country Status (31)

Country Link
US (1) US10179780B2 (tr)
EP (1) EP3176166B1 (tr)
JP (1) JP6279085B2 (tr)
KR (1) KR102474325B1 (tr)
CN (1) CN106661014B (tr)
AU (1) AU2015297501B2 (tr)
BR (1) BR112017001657B1 (tr)
CA (1) CA2956553C (tr)
CY (1) CY1121189T1 (tr)
DK (1) DK3176166T3 (tr)
ES (1) ES2712850T3 (tr)
HR (1) HRP20182084T1 (tr)
HU (1) HUE042576T2 (tr)
IL (1) IL250143B (tr)
LT (1) LT3176166T (tr)
ME (1) ME03319B (tr)
MX (1) MX370524B (tr)
MY (1) MY180730A (tr)
NZ (1) NZ729068A (tr)
PH (1) PH12017500124A1 (tr)
PL (1) PL3176166T3 (tr)
PT (1) PT3176166T (tr)
RS (1) RS58315B1 (tr)
RU (1) RU2701515C2 (tr)
SA (1) SA517380787B1 (tr)
SG (1) SG11201700741WA (tr)
SI (1) SI3176166T1 (tr)
TR (1) TR201902314T4 (tr)
TW (1) TWI688563B (tr)
WO (1) WO2016017708A1 (tr)
ZA (1) ZA201700664B (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170217948A1 (en) * 2014-07-30 2017-08-03 Teijin Pharma Limited Xanthine oxidase inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
WO1996031211A1 (fr) 1995-04-07 1996-10-10 Teijin Limited Agent protecteur pour organe ou tissu
PT1020454E (pt) 1998-06-19 2009-12-21 Teijin Pharma Ltd Modificações polimórficas do ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazole-carboxílico e processos para a sua preparação
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
JP5222561B2 (ja) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2008126770A1 (ja) * 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
BRPI0810523A2 (pt) 2007-04-11 2014-10-21 Kissei Pharmaceutical Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
US20130190366A1 (en) 2010-02-19 2013-07-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
WO2011139886A2 (en) 2010-04-29 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Also Published As

Publication number Publication date
CA2956553C (en) 2023-03-21
AU2015297501A1 (en) 2017-03-09
PH12017500124B1 (en) 2017-05-29
DK3176166T3 (en) 2019-02-18
MX370524B (es) 2019-12-17
ES2712850T3 (es) 2019-05-16
SA517380787B1 (ar) 2021-03-11
PT3176166T (pt) 2019-02-04
IL250143A0 (en) 2017-03-30
WO2016017708A1 (ja) 2016-02-04
US10179780B2 (en) 2019-01-15
NZ729068A (en) 2022-05-27
EP3176166B1 (en) 2018-11-28
HUE042576T2 (hu) 2019-07-29
KR20170033320A (ko) 2017-03-24
PH12017500124A1 (en) 2017-05-29
CN106661014A (zh) 2017-05-10
LT3176166T (lt) 2019-01-10
MY180730A (en) 2020-12-08
EP3176166A4 (en) 2017-06-21
ZA201700664B (en) 2019-06-26
JPWO2016017708A1 (ja) 2017-04-27
ME03319B (me) 2019-10-20
RS58315B1 (sr) 2019-03-29
PL3176166T3 (pl) 2019-06-28
MX2017000412A (es) 2017-04-27
US20170247364A1 (en) 2017-08-31
EP3176166A1 (en) 2017-06-07
RU2017106052A3 (tr) 2018-08-28
IL250143B (en) 2019-11-28
CY1121189T1 (el) 2020-05-29
BR112017001657B1 (pt) 2023-01-17
RU2017106052A (ru) 2018-08-28
JP6279085B2 (ja) 2018-02-14
TWI688563B (zh) 2020-03-21
TW201617341A (zh) 2016-05-16
CA2956553A1 (en) 2016-02-04
SG11201700741WA (en) 2017-02-27
SI3176166T1 (sl) 2019-01-31
CN106661014B (zh) 2019-12-24
HRP20182084T1 (hr) 2019-02-08
AU2015297501B2 (en) 2019-07-04
KR102474325B1 (ko) 2022-12-05
BR112017001657A2 (pt) 2018-01-30
RU2701515C2 (ru) 2019-09-27

Similar Documents

Publication Publication Date Title
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
MD3442580T2 (ro) Metode de tratament pentru bolile colestatice și fibrotice
HUE046008T2 (hu) I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
BR112017006420A2 (pt) derivados de ácido borônico
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
LT3515910T (lt) 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ono dariniai ir jų naudojimas kaip fosfatatidilitinozitol 3-kinazės delta ir gama dvejopų inhibitorių
MX2018006802A (es) Derivados de fenilo como agonistas del receptor de canabinoides 2.
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
PH12017500123B1 (en) Crystal of azole benzene derivative
TR201902314T4 (tr) Azol benzen türevi ve bunun kristali.
EP3749647C0 (en) N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER
CL2012002452A1 (es) Procedimientos para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida; uno de sus compuestos interemdiarios; y la preparacion del mismo.
CO2018000953A2 (es) Asociación entre la 3 - [(3 - {[4- (4-morfolinilmetil) -1h-pirrol-2-il] metilen} -2-oxo-2,3-dihidro-1h-indol-5-il) metil ] -1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr
AR101362A1 (es) Derivado de azol benceno y forma cristalina del mismo
UA114081U (uk) 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої
TH168005B (th) สารอนุพันธ์เอโซล เบนซีน และรูปผลึกของสารนั้น
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
UA97633U (xx) 3-((2-хлоретил)тіо)-5-(4-метоксифеніл)-1н-1,2,4-триазол, що проявляє гіпоглікемічну активність
UA97377U (en) 3 - ((2-chloroethyl) thio) -5- (3,4,5-trimethoxyphenyl) -1h-1,2,4-triazole which exhibits hypoglycemic activity
TH168006B (th) สารอนุพันธ์เอโซล เบนซีน และรูปผลึกของสารนั้น
TH168005A (th) สารอนุพันธ์เอโซล เบนซีน และรูปผลึกของสารนั้น
UA93722U (uk) Похідне 3-тіо-1,2,4-триазолу, що проявляє туберкулостатичну дію